IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3Kδ Inhibitor Idelalisib.

ŠANDOVÁ, Veronika, Marek MRÁZ, Gabriela MLADONICKÁ PAVLASOVÁ, Václav ŠEDA, Veronika PALUŠOVÁ, Yvona BRYCHTOVÁ, S. FERNANDES, Michael DOUBEK, M. DAVIDS and J. BROWN. IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3Kδ Inhibitor Idelalisib. In XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 2021.

Basic information

• Original name: IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3Kδ Inhibitor Idelalisib.
• Authors: ŠANDOVÁ, Veronika, Marek MRÁZ, Gabriela MLADONICKÁ PAVLASOVÁ, Václav ŠEDA, Veronika PALUŠOVÁ, Yvona BRYCHTOVÁ, S. FERNANDES, Michael DOUBEK, M. DAVIDS and J. BROWN.
• Edition: XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), 2021.

Other information

• Type of outcome: Conference abstract
• Confidentiality degree: is not subject to a state or trade secret
• Organization unit: Central European Institute of Technology

Links

• MUNI/A/1595/2020, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VIII (Acronym: VýDiTeHeMa VIII)

Investor: Masaryk University

• NU20-03-00292, research and development project: Name: PRIORITIZACE KOMBINACÍ LÉČIV U CHRONICKÉ LYMFOCYTÁRNÍ LEUKÉMIE NA ZÁKLADĚ ANALÝZY ADAPTACE BUNĚK NA IBRUTINIB A IDELALISIB IN VIVO
• 802644, interní kód MU: Name: Signaling propensity in the microenvironment of B cell chronic lymphocytic leukemia (Acronym: LeukemiaEnviron)

Investor: European Union, ERC (Excellent Science)